Skip to content
ATLAS PREP HQ
Growth Hormone

PEG MGF

Pegylated mechano-growth-factor / IGF-1Ec E-domain-derived peptide analogue

Pegylated mechano-growth-factor research examining muscle-repair signaling and local tissue adaptation.

Preclinical Evidence

Route

Subcutaneous in the community experimental protocol.

Common format

2 mg vial

Research focus

muscle regeneration

Evidence level

Preclinical Evidence

Typical cycle

No established human cycle

Growth Hormone research motifGrowth Hormone

PEG MGF in 30 seconds

Atlas Fast Read

What it is

Pegylated mechano-growth-factor / IGF-1Ec E-domain-derived peptide analogue

Why people care

Pegylated mechano-growth-factor research examining muscle-repair signaling and local tissue adaptation.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Bottom line

PEG MGF is scientifically interesting for muscle regeneration, satellite cells, but the current case is driven mainly by cell and animal data.

Overview

What is PEG MGF?

PEG MGF is pegylated mechano-growth-factor / IGF-1Ec E-domain-derived peptide analogue. Pegylated mechano-growth-factor research examining muscle-repair signaling and local tissue adaptation.

Mechano-growth factor was described as an IGF-1 splice response to mechanical loading; pegylated analogues were later created to extend peptide half-life. PEG-MGF itself has not progressed through a standard human clinical-development program.

Mechanism

How it works

Based on the IGF-1Ec/mechano-growth-factor response to mechanical stress. The E-domain peptide is proposed to stimulate satellite-cell and tissue-repair pathways; pegylation is intended to prolong exposure.

Research areas

muscle regenerationsatellite cellsbone/cartilage repairexercise adaptation

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

No credible controlled human trials establish PEG-MGF for muscle growth, injury recovery, or athletic performance. Human claims are extrapolated from IGF-1/mechano-growth-factor biology rather than demonstrated for the pegylated research peptide.

Preclinical evidence

Cell and animal models suggest IGF-1Ec/E-domain-related effects on satellite cells, repair, and tissue growth. The pegylated product lacks a standardized translational evidence base.

Knowledge gaps

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

community sources experimental reference: 200–500 mcg/day. No human clinical dose exists.

Frequency

Once daily in the community protocol.

Timing

Often discussed around training, but optimal timing has not been established in humans.

Route

Subcutaneous in the community experimental protocol.

Cycle length

No established human cycle

Reconstitution

Community reference: 0.2 mL bacteriostatic water per 2 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C; avoid repeated freeze-thaw.

Monitoring

IGF-1, glucose, CK when clinically relevant, edema and unexpected tissue-growth symptoms; there is no validated PEG-MGF monitoring standard.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Human safety is unestablished. Potential IGF-related concerns include hypoglycemia, edema, headache, tissue overgrowth and injection reactions; pegylation can alter immunogenicity and distribution.

Contraindications

No approved contraindication profile exists. Active malignancy, hypoglycemia, proliferative disease, pregnancy/breastfeeding and serious endocrine disease are major reasons for avoidance.

Interactions

Interaction studies are absent. Combining with GH, IGF-1, insulin or glucose-lowering agents could amplify growth or glucose effects.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

PEG MGF is scientifically interesting for muscle regeneration, satellite cells, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Growth Hormone

Growth Hormone

CJC-1295 DAC

Long-acting GHRH analog research designed to extend growth-hormone signaling over multiple days.

Read guide

Growth Hormone

CJC-1295 NO DAC + Ipamorelin

GHRH plus growth-hormone secretagogue research intended to support more pulsatile GH release.

Read guide

Growth Hormone

GHRP-2

Ghrelin-receptor agonist research focused on stimulating growth-hormone secretion.

Read guide